CSF3 and infection: In a similar phase 3 study by Weber et al., in which 41% of patients experienced neutropenia and 22% had an infection, 34% received reactive G-CSF and dose reductions were required in 77% of participants (neutropenia was mentioned as a primary reason for dose reduction) [46].